Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

April 26, 2018

University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers. In addition to identification of specific genes that may drive these cancers and thus provide attractive targets for treatment, the researchers found that in several samples of advanced differentiated and anaplastic thyroid cancer (the most aggressive and dangerous forms of the disease), mechanisms meant to repair faulty DNA had been broken. These broken repair mechanisms led to a subset of thyroid cancers accumulating a high number of genetic alterations - and this "high mutation burden" is a marker recognized by the FDA to recommend treatment with anti-cancer immunotherapies.

"Anaplastic thyroid cancer is a particularly terrible cancer - people wonder what makes it so bad, and advanced thyroid cancer causes significant morbidity. I've had a very productive relationship with Foundation Medicine, primarily to study rare salivary gland cancers and I'm pleased that we've been able to extend our collaboration to the study of thyroid cancers to hopefully answer some of these questions," says Daniel Bowles, MD, clinical and translational investigator at CU Cancer Center and Head of Cancer Research at the Denver Veterans Administration Medical Center.

Bowles worked with first author Nikita Pozdeyev, MD, PhD, to analyze tumor samples submitted by oncologists from around the United States to Foundation Medicine for genetic analysis that could inform treatment strategies. Interestingly, the fact that clinicians who submitted these samples were specifically seeking possible treatment strategies meant that the majority of samples were from advanced cancers.

"Genetic analysis of early-stage thyroid cancers is most often not necessary - we successfully treat these tumors with surgery and radioactive iodine," Pozdeyev says. "But with distant metastases, genetic information becomes important for treatment. Because oncologists had sought this genetic information, our study is enriched for advanced cases."

The researchers point out that even large treatment centers are likely to only a few of these most dangerous, anaplastic thyroid cancers every year. Due to the current study's industry-academia collaboration, the researchers were able to explore 196 of these anaplastic thyroid cancers, "giving us sufficient analytical power to use machine learning and statistical analysis to make sense of the data," Pozdeyev says.

In addition to finding that some anaplastic thyroid cancers carried a high overall mutation burden that could make immunotherapy an attractive treatment option, the group found specific genetic changes driving anaplastic cancers, including amplifications of the genes KDR, KIT and PDGFRA. These genes encode a kind of on-off switch called "receptor tyrosine kinases" that many cancer cells use to speed their growth and proliferation. In this case, these receptor tyrosine kinases happen to be targeted by the drug lenvatinib, which earned FDA approval for use in kidney cancer. In collaboration with Drs. Bryan Haugen and Rebecca Schweppe, the researchers treated a cohort of thyroid cancer cell lines with lenvatinib, finding that it was the cell line with amplification of KDR, KIT and PDGFRA that was especially sensitive to the drug, hinting that treatment with lenvatinib may be an attractive strategy against a subset of anaplastic thyroid cancers.

"As a clinician, I learn from this study that every patient with advanced thyroid cancer that we consider for systemic therapy should be genotyped - knowledge of genetic background may affect how we treat that patient," Pozdeyev says. "There are many drugs targeting many genetic changes that are approved for other cancers, which we would not usually think to use in thyroid cancer. Some of the findings in this paper will potentially change that."
Results are published online ahead of print in the journal Clinical Cancer Research.

University of Colorado Anschutz Medical Campus

Related Thyroid Cancer Articles from Brightsurf:

Trends in the global burden of thyroid cancer
This study examined the worldwide trends of thyroid cancer from 1990 to 2017 according to geographic location, sex, age and socioeconomic factors.

Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.

Thyroid cancer, genetic variations, cell phones linked in YSPH study
Radiation from cell phones is associated with higher rates of thyroid cancer among people with genetic variations in specific genes, a new study led by the Yale School of Public Health finds.

AJR researchers take step toward automating thyroid cancer triage
An article published ahead-of-print in the April issue of the American Journal of Roentgenology (AJR) details how a Stanford University team developed a quantitative framework able to sonographically differentiate between benign and malignant thyroid nodules at a level comparable to that of expert radiologists, which could provide second-opinion malignancy risk estimation to clinicians and ultimately help decrease the number of unnecessary biopsies and surgical procedures.

Thyroid cancer rates in US
An analysis suggests rates of thyroid cancer in the US appear to have plateaued in recent years after decades on the rise.

Using artificial intelligence to predict risk of thyroid cancer on ultrasound
New study uses machine learning on ultrasound images of thyroid nodules to predict risk of malignancy.

For low-risk thyroid cancer patients, less may be more for post-surgery surveillance
Patient self-advocacy is important, and although a maximizing preference may be advantageous in many situations, new research led by the University of Michigan Rogel Cancer Center shows that, in the case of long-term surveillance of treated, low-risk thyroid cancer, health care ''maximizers'' consume more health care resources -- such as doctor visits and diagnostic imaging tests -- which drive up costs without a clear improvement in outcomes.

New test for thyroid cancer could prevent unnecessary surgery
Each year, thanks to inconclusive tests for thyroid cancer, thousands of people undergo unnecessary surgeries to remove part or all of their thyroids.

Raman spectroscopy poised to make thyroid cancer diagnosis less invasive
Researchers have demonstrated that an optical technique known as Raman spectroscopy can be used to differentiate between benign and cancerous thyroid cells.

Are doctors treating more thyroid cancer patients than necessary?
New research may help change treatment practices for patients diagnosed with low risk thyroid cancer.

Read More: Thyroid Cancer News and Thyroid Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to